Apple stock rises after the tech giant posts better-than-expected earnings and guides for solid growth, while Intel’s ...
The U.S. Food and Drug Administration said it approved Boston-based Vertex Pharmaceuticals' Journavx for short-term pain that ...
On Thursday, in a major step forward in pain management, the U.S. Food and Drug Administration has approved a new nonopioid ...
While America retains a gold standard for airline safety, there are stresses on the US air travel system that have been apparent in a series of near tragedies in recent years. Aviation experts have ...
Vertex Pharmaceuticals (VRTX – Research Report), the Healthcare sector company, was revisited by a Wall Street analyst today. Analyst Terence ...
A new type of non-opioid painkiller, aimed at treating short-term pain in adults, has been approved by the US Food and Drug Administration (FDA). The drug suzetrigine, known by its brand name Journavx ...
Barclays analyst Gena Wang raised the firm’s price target on Vertex Pharmaceuticals (VRTX) to $435 from $418 and keeps an Equal Weight rating ...